Should active injecting drug users receive treatment for chronic hepatitis C?

Arquivos de Gastroenterologia

Volumn 47, Issue 3, 2010, Pages 238-241

  Papadopoulos, Vasileios ^a   Gogou, Aikaterini ^a   Mylopoulou, Theodora ^a   Mimidis, Konstantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Drug users; Hepatitis C, chronic; Interferon alfa 2; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; CLINICAL EVALUATION; DRUG USE; FEMALE; HEPATITIS C; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RIBAVIRIN; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 78649961994     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032010000300005     Document Type: Article

References (13)

1. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis. 2005;40(Suppl 5):s330-5.
2. Belfiori B, Chiodera A, Ciliegi P, Tosti A, Baldelli F, Stagni G, Francisci D. Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicenter study. Eur J Gastroenterol Hepatol. 2007;19:731-2. (Pubitemid 47067077)
3. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, Francisci D. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis. 2009;41:303-7.
4. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, Meili D; Swiss Hepatitis Cohort Study. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747-52.
5. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C [abstract]. Aliment Pharmacol Ther 2008; 29:38-45.
6. Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, Razafandratsima N, Emmanuelli J, Guibart G, Barin F, Desenclos LC. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009;9:113.
7. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120-4.
8. Reimer J, Schulte B, Castells X, Schafer I, Polywka S, Hedrich D, Wiessing L, Haasen C, Backmund M, Krausz M. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis. 2005;40(Suppl 5):s373-8.
9. Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet. 2009;373:2090-1.
10. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625-33.
11. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336-45.
12. Zanini B, Lanzini A. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antivir Ther. 2009;14:467-79.
13. Zule WA, Costenbader EC, Coomes CM, Wechsberg WM. Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health. 2009;99(Suppl 1):s180-6.